Trials / Completed
CompletedNCT00478374
Sorafenib With TACE to Treat Hepatocellular Carcinoma
Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- University of Bern · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not treated by chemoembolisation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | Sorafenib 400mg bid |
| PROCEDURE | Transarterial chemoembolisation with doxorubicin | Transarterial chemoembolisation (TACE) |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2007-05-24
- Last updated
- 2010-11-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00478374. Inclusion in this directory is not an endorsement.